New direct-acting antiviral therapies for treatment of chronic hepatitis C virus infection

Gastroenterology and Hepatology

Volumn 11, Issue 7, 2015, Pages 458-466

  Kardashian, Ara A ^a   Pockros, Paul J ^b  

^a SCRIPPS CLINIC   (United States)

^b SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

Direct acting antiviral agents; Hepatitis C virus; Nucleoside inhibitors; Protease inhibitors; Special populations

Indexed keywords

ANTIVIRUS AGENT; DASABUVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RITONAVIR; SIMEPREVIR; SOFOSBUVIR;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CHRONIC KIDNEY DISEASE; GENOTYPE; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; MIXED INFECTION;

EID: 84938601795     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-1765.
2. Afdhal N, Z euzem S, Kwo P, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
3. Afdhal N, Reddy KR, Nelson DR, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
4. Kowdley KV, Gordon SC, Reddy KR, et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-1888.
5. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222-232.
6. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594-1603.
7. Ferenci P, Bernstein D, Lalezari J, et al; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-1992.
8. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973-1982.
9. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-1614.
10. Zeuzem S, Dusheiko GM, Salupere R, et al; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993-2001.
11. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV g enotype 1 and HIV co-infection. JAMA. 2015;313(12):1232-1239.
12. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223-1231.
13. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375-2382.
14. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211-221.
15. Nelson DR, Cooper JN, Lalezari JP, et al; ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127-1135.
16. Muir AJ,Poordad F,Lalezari J,et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis JAMA. 2015;313 17 1736-1744.
17. Poordad F, Sievert W, Mollison L, et al; UNITY-1 Study Group. Fixed-dose combination th erapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA. 2015;313(17):1728-1735.
18. Fujii Y, Uchida Y, Mochida S. Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. Hepatology. 2015;61(1):400-401.
19. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075-1086.
20. Sulkowsk i M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV /hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087-1097.
21. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial [published online April 24, 2015]. Ann Intern Med. doi:10.7326/M15-0785.
22. Poordad F, L awitz E, Gutierrez JA, et al. C-SWIFT: Grazoprevir/elbasvir sofosbuvir in cirrhotic and noncirrhotic, treatment-naï ve patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks. J Hepatol. 2015;(62):S192.
23. Forns X, Gordon S, Zuckerman E, et al. Grazoprevir/elbasvir plus ribavirin for chronic HCV genotype 1 infection after failure of combination the rapy containing a direct-Acting antiviral agent [published online April 17, 2015]. J Hepatol. doi:10.1016/j.jhep.2015.04.009.
24. Jacobson I, Poordad F, Firpi-Morell R, et al. Efficacy and safet y of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis (C-SALT Part A). J Hepatol. 2015;(62):S193.
25. Roth D, Hezode C, Zuckerman E, et al. C-SURFER: grazoprevir plus elbasvir in treatment-naï ve and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. J Hepatol. 2015;(62):S263.
26. Gane EJ, Hylan d RH, An D, et al. Once-daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis results in high rates of SVR12: the ELECTRON-2 study. Hepatology. 2014;60(4 suppl):236A.
27. Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology. 2014;60(4 suppl):LB-11.
28. Younossi Z, Saab S, Ahmed A, Gordon SCA. Decision-Analytic Markov model To evaluate the health outcomes of ledipasvir/sofosbuvir (LDV/SOF) for patients with chronic hepatitis C (HCV) genotype 1 (GT1) infection. Hepatology. 2014;60(4 suppl):1043A .
29. Ahmed A, Gordon SC, Saab S, Younossi Z. Evaluation of the health outcomes for ledipasvir/sofosbuvir in early vs. delayed treatment according to fibrosis stage of patients with chronic hepatitis c virus (HCV) gen otype 1 infection: results from a decision-Analytic Markov model. Hepatology. 2014;60(4 suppl):1041A.
30. Pollock A. Sales of Sovaldi, new Gilead hepatitis C drug, soar to 10.3 billion. New York Times. Feb 3, 2015.
31. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed F ebruary 2, 2015.
32. Pockros PJ. Direct-Acting antivirals for the treatment of hepatitis C virus infection. UpToDate. Accessed February 28, 2015.